PharmaCyte Biotech
PMCB
32 hedge funds and large institutions have $8.79M invested in PharmaCyte Biotech in 2022 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 10 increasing their positions, 6 reducing their positions, and 1 closing their positions.
800% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 1
67% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 6
28% more funds holding
Funds holding: 25 → 32 (+7)
0.4% more ownership
Funds ownership: 18.53% → 18.93% (+0.4%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% less capital invested
Capital invested by funds: $8.83M → $8.79M (-$36K)
95% less call options, than puts
Call options by funds: $100K | Put options by funds: $2.01M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KPF
K2 Principal Fund
Toronto,
Ontario, Canada
|
+$199K |
| 2 |
Group One Trading
Chicago,
Illinois
|
+$151K |
| 3 |
Simplex Trading
Chicago,
Illinois
|
+$120K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$110K |
| 5 |
SC
Shay Capital
New York
|
+$83.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$468K |
| 2 |
Morgan Stanley
New York
|
-$130K |
| 3 |
FIA
FNY Investment Advisers
New York
|
-$95.7K |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$35.2K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$12.7K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
26
UBS Group
Zurich,
Switzerland
| – | -$12.7K | -5,823 | -100% |
|
27
JP Morgan Chase
New York
| – | -$6K | -2,723 | Closed |
|
28
Carson Wealth (CWM LLC)
Omaha,
Nebraska
| – | +$2 | +1 | New |
|
29
Wells Fargo
San Francisco,
California
| – | +$24 | +11 | +9% |
|
|
HFS
30
Heritage Financial Services
Westwood,
Massachusetts
| – | +$146 | +67 | New |
|
PMCB Hedge Fund Activity: Q2 2022 in Review
32 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in PharmaCyte Biotech (PMCB) for Q2 2022, worth a combined $8.79M — down 0.41% from $8.83M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new PMCB positions and 1 closed out — a net gain of 8 holders — while 10 added to existing stakes and 6 trimmed.
The largest buyer was K2 Principal Fund, opening a new position worth an estimated $199K. The largest seller was Sabby Management, cutting an estimated $468K.
- 32 institutional investors held PharmaCyte Biotech (PMCB) as of Q2 2022, up from 25 in Q1 2022.
- Funds reported $8.79M of PharmaCyte Biotech stock for Q2 2022, down 0.41% quarter-over-quarter.
- 9 funds opened new PharmaCyte Biotech positions in Q2 2022 and 1 closed out, a net change of +8 holders.
- The largest PharmaCyte Biotech buyer in Q2 2022 was K2 Principal Fund, an estimated $199K added.
- The largest PharmaCyte Biotech seller in Q2 2022 was Sabby Management, an estimated $468K sold.
Based on aggregated 13F filings for Q2 2022.